TCGA-BB-4227-01A-01R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- GLYCOLYSIS+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- CHOLESTEROL_HOMEOSTASIS+0.280
- PROTEIN_SECRETION+0.260
- ADIPOGENESIS+0.250
- FATTY_ACID_METABOLISM+0.240
- HYPOXIA+0.210
- E2F_TARGETS+0.170
- SPERMATOGENESIS+0.170
- BILE_ACID_METABOLISM+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.470
- MYC_TARGETS_V2-0.430
- ALLOGRAFT_REJECTION-0.410
- WNT_BETA_CATENIN_SIGNALING-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- TGF_BETA_SIGNALING-0.360
- IL6_JAK_STAT3_SIGNALING-0.330
- MYOGENESIS-0.320
- APICAL_JUNCTION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR17866837 | — | — | 0.833 |
| 2 | SRR1516065 | — | — | 0.792 |
| 3 | SAMN03290933 | — | — | 0.784 |
| 4 | R286 | — | — | 0.783 |
| 5 | SRR8518435 | — | F | 0.771 |
| 6 | SRR33346944 | — | — | 0.767 |
| 7 | DRR168601 | — | — | 0.765 |
| 8 | R55 | — | — | 0.765 |
| 9 | R360 | — | — | 0.758 |
| 10 | SRR12202430 | — | — | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.010 | Inavolisib | — uncovered |